Neurocompute scores biomedical literature, surfaces overlooked patterns, and turns Parkinson’s research into a living discovery terminal.
B grade · PMID 42012760
View analysis →B grade · PMID 41977401
View analysis →B grade · PMID 41997082
View analysis →B grade · PMID 41898603
View analysis →B grade · PMID 42035925
View analysis →B grade · PMID 41994569
View analysis →B grade · PMID 42033865
View analysis →B grade · PMID 41999339
View analysis →B grade · PMID 41977320
View analysis →B grade · PMID 41951774
View analysis →In 6‑OHDA SH‑SY5Y cells and unilateral 6‑OHDA rats, Antrodia cinnamomea conjugated to citrate‑stabilized silver nanoparticles improved cell survival and motor behavior, reduced oxidative stress, inflammation, and apoptosis, increased TH/PI3K and lowered α‑synuclein and caspase‑3, with partial…
This provides proof‑of‑concept for a multitarget neuroprotective strategy addressing oxidative stress, neuroinflammation, apoptosis and α‑synuclein—relevant to PD drug discovery—while translation is tempered by use of an acute toxin model and potential safety/PK issues with silver nanoparticles and…
In RAW264.7 macrophages, miR-369-3p directly targets and reduces LRRK2 expression, limits LPS‑induced NF-κB nuclear translocation, restores autophagy markers (LC3II/I, BECLIN-1, p62) and shifts cytokine output toward an anti-inflammatory profile.
By showing a miRNA that modulates LRRK2-driven inflammation and autophagy, the study suggests a tractable therapeutic avenue relevant to PD-associated immune/gut inflammation, although results are limited to a murine macrophage line and require neuronal and in vivo validation for translational…
This review synthesizes exosome biology and translational advances across neurodegenerative diseases, emphasizing exosome-mediated propagation of misfolded proteins (including α-synuclein), disease-specific exosomal biomarkers, and engineered/ stem cell-derived exosome therapeutics for CNS delivery.
For Parkinson's research it aggregates actionable leads—α-synuclein-containing exosomes as both biomarkers and pathogenic vectors, plus strategies for exosome-based CNS delivery—while clearly outlining translational barriers (scalability, PK/PD, immunogenicity) that prioritize immediate preclinical…
This review links impaired adult neurogenesis in the SGZ and SEZ to chronic inflammation, mitochondrial dysfunction, oxidative stress, and accumulation of β-amyloid, tau, and α-synuclein in AD and PD, and discusses non‑pharmacological (diet, exercise) and targeted strategies to stimulate…
Identifies actionable, disease-relevant mechanisms (inflammation, mitochondria, α-synuclein) and translational interventions that could be leveraged to restore neurogenic capacity and potentially slow Parkinson's disease progression, while noting the key challenge of achieving functional…
A recent mechanistic review highlighting galectins (notably galectin-1/3/4/8/9) as multifunctional regulators of microglial activation, vesicle/lysosomal damage sensing, autophagy, and the aggregation/propagation of misfolded proteins including α‑synuclein across CNS disease models.
Highly relevant for Parkinson's drug discovery because galectins intersect α‑synuclein pathology, lysosomal/autophagic clearance, and neuroinflammation—making them candidate biomarkers and stage-specific therapeutic targets, though their context-dependent pro- versus anti‑inflammatory roles imply…
A mechanism-focused review summarizing pharmacological approaches that modulate the microbiota-gut-brain axis—microbiota-directed therapies, immune-inflammatory modulators, neurotransmitter-targeting agents, and barrier-restoring strategies—with an eye toward translational applications across…
Highlights PD-relevant mechanisms (gut dysbiosis, neuroinflammation, BBB/intestinal barrier dysfunction) and organizes actionable intervention classes that can guide prioritization and repurposing of therapeutics for Parkinson's research and clinical translation.
Review synthesizing evidence that polyphenols and exercise reshape the gut microbiota to produce metabolites (SCFAs, urolithins, indoles) that activate Nrf2 signaling and thereby support antioxidant, mitochondrial, and anti-inflammatory defenses relevant to neurodegeneration including Parkinson's…
Connects a mechanistic, actionable gut microbiome→Nrf2 axis to pathways central to Parkinson's (oxidative stress, mitochondrial dysfunction, neuroinflammation), pointing to microbiome-informed dietary/exercise interventions, metabolite biomarkers, and metabolite- or Nrf2-targeted adjunct therapies…
This study reports zinc–tannic acid coordination nanoparticles that scavenge ROS, inhibit and disaggregate α‑synuclein fibrils, preserve mitochondrial function, and rescue motor/cognitive deficits and dopaminergic neuron loss in a PD mouse model without overt toxicity.
Multimodal nanoparticle therapy targets both α‑syn aggregation and oxidative stress with in vivo efficacy and low toxicity, offering a translationally promising disease-modifying approach for Parkinson’s therapeutics.
The paper reports MTP150, a polyfunctionalized N-arylsulfonyl indole that ameliorates protein aggregation, neuroinflammation, oxidative stress, mitochondrial dysfunction, and DNA repair deficits, improving motor performance and neuroprotection in C. elegans, Drosophila, and cellular models of…
By engaging multiple PD-relevant mechanisms (aggregation, mitochondria, inflammation, DNA repair) and showing efficacy across invertebrate and cell models, MTP150 is a promising preclinical epigenetic-based lead that merits mammalian validation and translational development.
ADT-OH, a slow-release H2S donor, induces SQR-dependent mitochondrial uncoupling that activates PINK1–PARKIN–mediated mitophagy in microglia, preventing mtDNA release and cGAS–STING inflammatory signaling in α-synuclein models and rescuing dopaminergic neurons and motor deficits in PD mice.
This paper identifies a mechanistically actionable compound that links mitophagy induction to suppression of microglia-driven cGAS–STING inflammation and demonstrates in vivo neuroprotection, making ADT-OH a promising lead for PD therapeutic development or repurposing.
In a rotenone rat model of Parkinson's disease, oral empagliflozin improved motor behavior, preserved substantia nigra and striatal dopaminergic markers and dopamine levels, reduced α-synuclein aggregation and microglial activation, replenished glutathione, and suppressed…
Provides actionable preclinical evidence that an FDA‑approved SGLT2 inhibitor can target NLRP3-driven neuroinflammation and pyroptosis—supporting repurposing potential for disease-modifying PD therapy—while translation is limited by reliance on a single rotenone toxin model and absence of CNS…
The study demonstrates that MSA patients harbor clonally expanded, brain‑homing cytotoxic CD8+ (and CD4+) T cells that recognize α‑synuclein in an HLA‑dependent manner and exhibit inflammatory and cytotoxic transcriptional programs.
By implicating antigen‑specific adaptive immunity against α‑synuclein and defining HLA‑restricted T cell clonotypes and effector programs, the work points to actionable targets (antigen presentation, T cell responses, biomarkers) for immunomodulatory or antigen‑specific therapies relevant to…
In an MPTP mouse model, TRPV4 activation disrupts the autophagy-lysosomal pathway causing accumulation of α‑synuclein and cognitive deficits, while TRPV4 knockdown reduces α‑syn pathology and neurotoxicity.
Pinpoints TRPV4 as a druggable regulator of autophagic/lysosomal proteostasis (with readouts like LC3B, p62, LAMP1, TFEB), offering a mechanistically actionable target and biomarkers for developing PD therapeutics.
In a rotenone mouse model of Parkinsonism, oral luteolin (100–200 mg/kg) reduced oxidative stress and neuroinflammation, improved motor behavior and neuronal histology, and modulated TNF-α, FMRP, serotonin, and tyrosine hydroxylase expression.
The study supports luteolin as a neuroprotective candidate acting on mitochondria-linked toxin pathology and inflammatory pathways—relevant to PD biology and repurposing—but translational potential is limited by high doses, no PK/α‑synuclein or target-validation data, and reliance on a single toxin…
In an AlCl3-induced Drosophila Alzheimer's-like model, garcinol from Garcinia indica reduced behavioral deficits, oxidative stress, AChE activity, pro-inflammatory cytokines, and apoptotic markers, supported by antioxidant assays and in silico docking to Aβ, AChE, and β-secretase.
While the antioxidant, anti-inflammatory and apoptosis-modulating effects are mechanistically relevant to neuroprotection and could inform PD lead discovery, the study is AD-focused, lacks PD-specific targets (α‑synuclein/mitochondria), and has no mammalian validation, limiting immediate…
A mechanistic kinetic model implicates DOPAL-driven impairment of vesicular dopamine storage in a tri-phasic decline of putamen dopamine and predicts that genetic/environmental hits accelerate symptomatic PD while early, combined interventions (MAO inhibition, levodopa, antioxidants, and improved…
Provides actionable, translatable targets (vesicular sequestration, DOPAL detoxification, MAO) and supports timing- and multi-target–based neuroprotective strategies to prioritize preclinical and clinical interventions for delaying or preventing Parkinson's disease.
In a mouse alpha-synuclein PFF model, aged wild-type mice develop a type I interferon–dependent gastrointestinal inflammatory response that is absent in IFNAR1 knockout animals and is recapitulated in intestinal organoids via enteroendocrine uptake of α‑syn, implicating IFN signaling in gut-brain…
Points to type I IFN/IFNAR1 signaling as a actionable, targetable mechanism linking brain α‑syn pathology to gut inflammation, supporting therapeutic strategies (e.g., IFNAR blockade or JAK inhibition) to limit PD progression along the gut–brain axis.
This review synthesizes preclinical and limited clinical evidence that dietary bioactive compounds and physical exercise converge on a 'neuro‑nutritional‑metabolic axis'—encompassing gut‑brain signaling, metabolic regulation, mitochondrial function, and anti‑inflammatory/neurotrophic pathways—to…
The paper highlights modifiable, mechanistically plausible targets (dietary bioactives, exercise, gut‑brain and metabolic pathways, mitochondria, inflammation) that could inform multimodal neuroprotective interventions, biomarker selection, and translational studies for Parkinson's despite limited…
This chapter synthesizes evidence that microtubule dysregulation, driven by PD-linked genes (SNCA, Parkin, PINK1, LRRK2), impairs axonal transport and mitophagy, amplifies α-synuclein aggregation, and reviews MT-stabilizing agents and LRRK2-targeted approaches as therapeutic avenues.
By connecting cytoskeletal dysfunction to core PD mechanisms (α-synuclein pathology, mitochondrial quality control) and evaluating actionable interventions and translational challenges, the work identifies concrete targets and strategies useful for drug discovery and target prioritization.
Comprehensive review of nanoparticle platforms for CNS therapy that summarizes BBB-targeting strategies, payloads (drugs, RNA, nanobodies), preclinical efficacy across neuropsychiatric disorders including Parkinson's, and a translational 'playbook' for clinical development.
Identifies actionable translational opportunities—nanoparticle delivery to address neuroinflammation, bioenergetics, and gut–brain routes and concrete CMC/PKPD and biomarker needs—making it a useful roadmap for advancing Parkinson's-targeted therapeutics.
